Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial
Eytan M. Stein, Amir T. Fathi, Courtney D. DiNardo, Daniel A. Pollyea, Gail J. Roboz, Robert Collins, Mikkael A. Sekeres, Richard M. Stone, Eyal C. Attar, Mark G. Frattini, Alessandra Tosolini, Qiang Xu, Wendy L. See, Kyle J. MacBeth, Stéphane de Botton, Martin S. Tallman, Hagop M. Kantarjian
Dive into the research topics of 'Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial'. Together they form a unique fingerprint.